Phase I randomized, double-blind, placebo-controlled, single ascending dose study of RGLS4326 in healthy volunteers

Trial Profile

Phase I randomized, double-blind, placebo-controlled, single ascending dose study of RGLS4326 in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs RGLS 4326 (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 07 Mar 2018 According to a Regulus Therapeutics media release, company planning for the multiple ascending dose (MAD) portion is underway
    • 07 Mar 2018 According to a Regulus Therapeutics media release, Data from this study in healthy volunteers will provide pharmacokinetics and safety data, and the study is currently on track for completion in the third quarter 2018.
    • 19 Dec 2017 According to a Regulus Therapeutics media release, dosing of the first cohort of healthy volunteers has been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top